Dr. Shapiro believes that cosmetic considerations are crucial and are achieved by meticulous attention to detail, newly refined minimally invasive surgical techniques, and working closely with our team of plastic reconstructive surgeons. He was one of the first surgeons at NYU Medical Center to perform, critically evaluate, and refine the technique of sentinel lymph node mapping and biopsy in patients with melanoma. After performing this technique in several hundred patients with melanoma, he has adapted it successfully to the treatment of patients with cancer of the breast and tumors of the skin and soft tissues. Dr Shapiro currently has the largest experience with nipple areolar sparing mastectomy and has successfully performed more of these complex procedures than all other oncologic surgeons at NYU combined. He has published over 100 peer-reviewed articles, book chapters, and abstracts, and has lectured regionally, internationally, and through the media and was recently featured prominently in an EMMY award winning television program addressing the treatment of young women with breast cancer. He is also a frequent speaker at SHARE, where he helps breast cancer patients and their families to better understand their pathology reports and treatment options. Dr. Shapiro has been intimately involved in the Melanoma Vaccine Program at NYU Medical Center, and to date has personally treated over 700 melanoma patients with immunotherapy. For the past 19 years he has been involved as an investigator in numerous clinical trials of biological and chemotherapeutic agents for patients with melanoma and breast cancer. In 1993 he created the first multidisciplinary oncology clinic at NYU Medical Center when he became Director of and reorganized the Breast Cancer service at Bellevue Hospital. The success of that program serves as a model of how to deliver efficient state-of-the-art multidisciplinary care to patients with cancer in a non-threatening and compassionate environment.

More recently, he has created and directs an interdepartmental Multidisciplinary Melanoma Conference, which meets each month to review the care of patients with melanoma at the Cancer center. In addition, he is a member of the Melanoma Clinical Trials Review Committee, through which new treatment modalities are presented and critically evaluated before being initiated, and is a founding member of the internationally respected NYU Interdisciplinary Melanoma Cooperative Group of physicians and researchers dedicated to the study and treatment of malignant melanoma .Currently Dr Shapiro has been appointed as the Director of Surgical Oncology Operations at the NYU Clinical Cancer Center and serves as a liason to the Department of Surgery. Dr. Shapiro created and maintains a Melanoma and Breast Cancer Research Fund at the NYU Clinical Cancer Center and has generated over $3 million dollars for oncologic research and resident training at NYU. He also works closely with medical students, residents, and fellows in educating them on how to attend to the medical and emotional needs of patients and their families.

Dr. Shapiro is a native New Yorker who, after graduating Summa Cum Laude from the University of Pennsylvania, attended NYU School of Medicine where he was elected to Alpha Omega Alpha. He completed an internship and residency in General Surgery at NYU, serving as Chief and Executive Chief resident under Dr. Frank C. Spencer. After his residency, he accepted the Landsberg-Zale Fellowship in Surgical Oncology at NYU. During that period he also studied, in the basic science research laboratory, the complex relationship between tumor metastasis and angiogenesis. This activity led to numerous publications and a National Institute of Health (NIH) Career Development Award Grant. Dr. Shapiro is an active member of many medical societies, including the American College of Surgeons, Society of Surgical Oncology, American Society of Clinical Oncology, American Association for Cancer Research, Alpha Omega Alpha, Association for Academic Surgery, American Society of Breast Surgeons. He is listed in numerous top doctors registries including Castle Connolly Top Doctors New York, New York Magazine, and Americas Top Doctors for Cancer.

UNIVERSITY OF PENNSYLVANIA 1984
Philadelphia, Pennsylvania
Bachelor of Arts, Biological Basis of Behavior


[ Back to Top ]

NEW YORK UNIVERSITY/BELLEVUE HOSPITAL / 1988-1993
MANHATTAN VETERANS ADMINISTRATION HOSPITAL
Internship and Residency in General Surgery
Chief Resident 1992-1993
Executive Chief Resident

- American Society of Breast Surgeons 2006-present
- Metropolitan Breast Group 2005-present
- Society of Surgical Oncology, Active Member 2004-present
- New York Surgical Society 2004-present
- International Sentinel Node Society, Active Member 2004-present
- NYU Cancer Institute, Active Member 1997-present
- American Society of Clinical Oncology, Active Member 1996-present
- American Association for Cancer Research, Active 1996-present
- New York County Medical Society 1996-present
- Association for Academic Surgery, Active Member 1994-present
- American College of Surgeons, Fellow 1998-present
- Alpha Omega Alpha, New York University 1988
- Phi Beta Kappa, University of Pennsylvania 1984
- Summa Cum Laude, University of Pennsylvania 1984
- New York Magazine Best Doctors New York 2008-present
- Best Doctors Best Doctors in America 2007-present
- Castle Connolly Guide Top Doctors New York 2004-present

[ Back to Top ]

NYU Cancer Institute

Clinical Operations Committee, Chair 2010
Melanoma Clinical Trials Committee 2002-present
Interdisciplinary Melanoma Group, Co-Chair 2002-present
Editorial Board, Cancer Institute News 2001-2008
Executive Fund Raising Task Force 2009-present

SHARE

Educational Speaker, Outreach, Education 2004-present
Dinner Committee A Second Helping of Life 2004-2008



[ Back to Top ]

New York State Health Science Research Board 1999-2000
Breast Cancer Research Education-Empire Program
Co- investigator: "Cellular Responses During Neoadjuvant
Paclitaxel Therapy"


[ Back to Top ]

Interdisciplinary Melanoma Cooperative Group (IMCG) 2006-2010
Co - Clinical Director

Melanoma SPORE Group 2009-2010
Clinical Leader Project II

Reponse, Resistance and Metastasis of Locally 2008-2010
Advanced Breast Cancer (LABC Stage 2B-3C) In A
Multiethnic Cohort (DOD)
Co-Investigator

Hypo-fractionated Conformational Radiation Therapy to 2009-2010
Tumor Bed After Segmental Mastectomy
Co-Investigator

Phase I-II Study of Hypo-Fractionated Adjuvant Breast 2009-2010
Radiation Therapy in Women With Ductal Carcinoma
In-Situ
Co-Investigator

Image Guided Radiotherapy (IGPT) for Prone Partial 2007
Breast Irradiation (PBI)
Co-Investigator

A Randomized Controlled Trial of Melanoma 2004-2007
Treatment: Comparison of Dendritic Cells versus
Montanide to Stimulate Anti-tumor Immunity (NYU 02-10)
Co-Investigator

A Phase I Study using Vaccination with NYU-ESO-1 2005-2007
Recombinanta Protein Mixed with CpG7909 and
Montanide ISA-51 in Patients with Cancers That Often
Express NY-ESO-1
Co-Investigator

NY-ESO-1 Protein Vaccination in Malignant Melanoma 2005-2007
Administered with Imiquimod as an Adjuvant (NYU 04-53)
Co-Investigator

Establishment of a Melanoma Immunology Laboratory 2004-2007
For the NYU Cancer Institute Vaccine Program
(NYU 04-11)
Co-Investigator

Development of NYU Interdisciplinary Melanoma 2003-2007
Cooperative: Clinicopathological Database (NYU02-20)
Co-Investigator

Phase II Trial of a Polyvalent Vaccine in IL-2 + GM-CSF 2000
Liposomes for Stage IIB and III Melanoma.
Co-investigator

Phase I-II Study of Conformal Radiation Therapy in 2000
Post-Menopausal Women with T1 Breast Cancer.
Co-investigator

Acculturation, Traditionalism, and Cultural Beliefs 2000
Among Hispanic Women With a Positive Mammogram:
The Impact of Care Seeking Behavior and Disease Stage
In Breast Cancer.
Co-Principal Investigator

Herceptin and Paclitaxel in Locally Advanced Breast 1999-2000
Cancer with Her-2 Overexpression (NYU 99-01).
Co-Investigator

Phase II Trial of the Effects of Interferon -2b on the 1998-2000
Immunogenicity of Polyvalent melanoma Antigen Vaccine
In Patients with Stage III Malignant Melanoma
Co-investigator

Phase I/II Trial of Polyvalent Melanoma Vaccine in 1997-1999
GM-CSF Liposomes for Patients with Stage IV Melanoma
Principal investigator

Phase II Clinical Trial of Polyvalent Melanoma 1996-1999 Antigen Vaccine and Interleukin-2 Encapsulated into
Lipsomes in Patients with Disseminated Melanoma
Co-investigator NIH funded*

Multi-Modality Therapy for Stage III Breast Cancer: A 1996-present
Phase II Study with Biologic Correlates
Co-investigator

PhaseI/II Clinical Trial of Polyvalent Melanoma Antigen 1995-1997
Vaccine Admixed with QS-21 in Patients with Malignant
Melanoma.
Co-principal Investigator

Clinical Trial of Polyvalent Melanoma Vaccine and 1995-1998
Interferon-alpha in Patients with Malignant Melanoma.
Co-investigator

Phase Ib/II Trial of the Effect of Interferon alpha on the 1995-1998
Expression of Class I & II Alloantigens In Vivo in Humans
Co-investigator

Phase Ib Trial of IL-1 alpha Combined with High Dose 1994-1995
Cisplatnum in Patients with Metastatic Melanoma.
Assistant Investigator

Phase I Study of Polyvalent Melanoma Antigen 1993-1996
Vaccine and IL-2 Encapsulated in Liposomes in Patients
with Stage IV Malignant Melanoma.
Assistant Investigator

Phase II Randomized Study of Adjuvant Immunotherapy 1993-1998
of Malignant Melanoma with a Polyvalent Melanoma
Antigen Vaccine.
Assistant Investigator


[ Back to Top ]

"Surgical Treatment of Malignant Melanoma" Advances in
Dermatology 2009: NYU Medical Center, June 12, 2009.

"Surgical Treatment of Malignant Melanoma"
Outreach Skin Cancer Awareness Program, NYU Cancer
Institute, April 30, 2009.

"Current Surgical Treatment of Malignant Melanoma"
Outreach Skin Cancer Awareness Program, NYU Cancer
Institute, April 17, 2008.

"Update on Sentinel Lymph Node Biopsy for Malignant Melanoma", American Academy of Dermatology, San Antonio, Texas, February 1, 2008.

"Current Treatment of Malignant Melanoma" Grand Rounds, Institute of Plastic Reconstructive Surgery, NYU Medical Center, October 10, 2007.

"Current Indications for Sentinel Lymph Node Biopsy in Malignant Melanoma" American Academy of Dermatology, New York, August 3, 2007.

"Surgical Treatment of Malignant Melanoma" Advances in
Dermatology 2007: NYU Medical Center, June 16, 2007.

"The Multidisciplinary Treatment of Breast Cancer…What Every
Plastic Surgeon Needs to Know"Grand Rounds, Institute of Plastic Reconstructive Surgery, NYU Medical Center, February 28, 2007.

"Current Surgical Treatment and Indications for Immunotherapy
For Malignant Melanoma" Grand Rounds, Institute of Plastic
Reconstructive Surgery, NYU Medical Center, February 7, 2007.

"Pitfalls in the Diagnosis of Breast Cancer" Advances in General
Surgery, Staten Island University Hospital Symposium, Marco Island
Florida, November 30, 2006.

"Current Surgical Treatment of Malignant Melanoma" Advances in
General Surgery, Staten Island University Hospital Symposium, Marco
Island Florida, December 1, 2006.

"Sentinel Lymph Node Biopsy Update" Advances in Dermatology
2006, NYU Medical Center, June 16, 2006.

"Cutaneous Malignancies" Basic Science Review for Surgical
Residents, NYU Department of Surgery, May 24, 2006.

"Current Surgical Treatment of Malignant Melanoma"
Outreach Skin Cancer Awareness Program, NYU Cancer Institute,
April 26, 2006.

"Current Multidisciplinary Treatment of Breast Cancer"
Grand Rounds, Institute of Plastic Reconstructive
Surgery, NYU Medical Center, March 8, 2006.

"Sentinel Lymph Node Biopsy: Melanoma and Breast Cancer"
Clinical Update, Department of Nursing Surgical Services ,
NYU Medical Center, February 21, 2006.

"Surgical Treatment and Immunotherapy for Malignant
Melanoma" Grand Rounds, Institute of Plastic Reconstructive
Surgery, NYU Medical Center, September 7, 2005

"Surgical Treatment of Malignant Melanoma" Advances in
Dermatology 2005: NYU Medical Center, June 3, 2005.

"Surgical Management of Melanoma" Skin Cancer Seminar
Series 2005: NYU Cancer Institute, April 28, 2005.

"Current Surgical Treatment of Malignant Melanoma:
Update of Sentinel Node Biopsy" American Academy of
Dermatology 2005: New Orleans, Louisiana, February 22,
2005

"Surgical Treatment of Advanced Malignant Melanoma"
American Academy of Dermatology 2004: New York,
July 31, 2004.

"Malignant Breast Disease"
Basic Science Lecture, NYU Department of Surgery,
May 19, 2004.

"Current Surgical Treatment of Malignant Melanoma"
Outreach Skin Cancer Awareness Program, NYU Cancer Institute,
April 28, 2004.

"Sentinel Lymph Node Biopsy: Breast Cancer"
Grand Rounds, Department of OBGYN, NYU Medical Center,
April 21, 2004.

"Surgical Treatment and Immunotherapy for Malignant Melanoma"
Grand Rounds, Department of Dermatology, NYU Medical
Center, February 24, 2004.

"The Multidisciplinary Treatment of Malignant Melanoma"
Grand Rounds, Department of Surgery, Staten Island University Medical
Center, Staten Island, NY. June 20, 2003.

"Surgical Treatment and Immunotherapy for Malignant Melanoma"
Grand Rounds, Department of Plastic Reconstructive Surgery,
NYU Medical Center. April 2003; February 2002.

"Multidisciplinary Melanoma Conference - Director / Moderator"
NYU Cancer Institute, Monthly (Every 3rd Tuesday), 2003 - present.

"Beyond the Scalpel - Breast Cancer From The Surgeon's Point of
View" Invited Speaker, SHARE, New York, NY, October 30, 2003.

"Advances in Breast Cancer Treatment" Invited Speaker, Outreach
Program, Kaplan Comprehensive Cancer Center, NYU Medical
Center. October 25, 2001.

"Commentary on the Prognosis of Recurrent Melanoma" Invited Expert Speaker, NBC Nightly News, August 16, 2000.

"How to Understand Your Pathology Report" Invited Speaker, Outreach Program, SHARE, Queens, New York. March 3, 2000.

"How to Understand Your Pathology Report" Invited Speaker, Outreach Program, SHARE, New York, New York. March 24 2002, March 22, 2001, January 20, 2000, July 15 1999.

"Delivering Bad News to the Patient With Cancer" Invited Subject Taping, Video Collaboration SHARE and The Macy Initiative in Health Care Communication, NYU School of Medicine, New York. January 21, 2000.


[ Back to Top ]

Hamilton HK, Rose AE, Christos PJ, Shapiro RL, Berman RS, Mazumdar M, Ma MW, Krich D, Liebes L, Brooks PC, Osman I. Increased Shedding of HUi77 Correlates with Worse Prognosis in Primary Melanoma. J Transl Med. 2010. Feb 23; 8:19..

Warycha MA, Zakrewski J, Ni O, Shapiro RL, Berman RS, Pavlick AC, Polsky D, Mazumdar M, Osman I. Meta-Analysis of Sentinel Node Positivity in Thin (<1 mm). Cancer. 2009 Feb 15; 115(4): 869-79.

Wich L, Hamilton H, Shapiro RL, Pavlick AC, Berman RS, Polsky D, Goldberg J, Hernando E, Manga P, Krogsgaard M, Kamino H, Darvishian F, Orlow S, Oster H, Bhardwaj N, Osman I. The New York University Melanoma Cooperative Group: An Integrated Prospective Clinicopathological-Biospecimen Database to Advance Translational Research in Melanoma. Am J Transl Res 2009; 1(1): 35-43.

Firoz EF, Warycha M, Zakrzewski J, Pollens D., Wang G, Shapiro R, Berman R, Pavlick A, magna P, Oster H. Celebi JT, Kamino H, Darvishian F, Rolnitsky L, Goldberg JD, Osman I, Polsky D. Association of MDM2 SNP309 and Melanoma Onset in Women. Clin Cancer Res. 2009 Mar 24.

Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, adams S, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Lonadri S, Zavadil J, Osman I, Bhardwaj N. Immune Profile and Mitotic Index of Metastatic Melanoma Lesions Enhance TNM Staging in Predicting Patient Survival. 2009. Proc of Nat Acad Sci. Nov 13, 2009.

Zakrzewski J, Geraghty LN, Rose AF, Christos P, Mazumdar M, Krich D, Polsky D, Shapiro R, Berman R, Darvishian F, Pavlick A, Osman I. Predictors of Survival in Melanoma Patients with Brain Metastases. 2009. Submitted for publication.

Adams S, O'Neill D, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz C, Angiulli A, Ritter E, Shapiro RL, Berman R, Berner N, Shao Y, Manches O, Pan L, Hoffman E, Gnjatic S, Old L, Pavilick A, Bhardwaj N. Immunotherapy for Malignant Melanoma Using Recombinant NY-ESO-1 Protein and TLR 7 Agonist Imiquimod as Vaccine Adjuvant.
J Immunol 2008.181: 776-784.

Shanker BA, Guth AA, Roses DF, Axelrod DA, Singh B, Toth H, Shapiro RL, Hiotis K, Cangiarella JF. Trends in Breast Cancer Surgery. An Institutional Experiemce Between 1995-2005. Breast Cancer: Basic and Clinical Research; April 2008.

Ng B, Zakreewski J, Warchya M, Christos PJ, Shapiro R, Berman R, Pavlick AC, Polsky D, Mazumdar M, Montgomery A, Liebes L, Brooks PC, Osman I. Shedding of Distinct Cryptic Collagen Epitope (HU177) in Sera of Melanoma Patients. Clin Cancer Research. 2008 Oct 1; 14(19): 6253.

Warchya MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Pavlick AC, Kopf AW, Polsky D, Osman I. Changes in the Presentation of Nodular and Superficial Spreading Melanomas Over 35 Years. Cancer. 2008 Nov 5; 113(12): 3341-3348.

Hamilton HK KD, Christos PJ, Shapiro RL, Berman RS, Pavlick AC, Polsky D, mazumdar M, Liebes L, Brooks PC, Osman I. Increased HU177 Shedding Correlates with Worse Prognosis in Primary Melanoma. Submitted for publication.

Velazquez EF, Yancowitz M, Pavlick A, Berman R, Shapiro RL, Bogunovic D, O'Neill D, Yu YL, Spira J, Christos PJ, Zhou XK, Mazumdar M, Nanus DM, Liebes L, Bhardwaj N, Polsky D, Osman I. Clinical Relevance of Neutral Endopeptidase (NEP/CD10) in Melanoma. J Translational Medicine. 2007, 5:2.

Velazquez EF, Jungbluth AA, Yancovitz M, Adams S, O'Neill D, Zavilevich K, Albukh T, Pavlick A, Polsky D, Shapiro R, Berman R, Spira J, Busam K, Osman I, Bhradwaj N. Expression of the Cancer Testis (CT) Antigen NY-ESO-1 in Primary and Metastatic Malignant Melanoma (MM), Correlation with Serology and Prognostic Factors. Cancer Immunology 2007 July 12;7:11.

Wen YH, Giashuddin S, Shapiro RL, Velazquez E, Melamed J. Unusual Occurrence of a Melanoma with Intermixed Epithelial Component: A True Melanocarcinoma? Am J Dermatopathology. 29(4):395-399. 2007.

Yancovitz M, Yoom J, Mikhail M, Gai W, Shapiro RL, Berman RS, Pavlick A, Chapman PB, Osman I, Polsky D. Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma. Journal of Molecular Diagnostics. 2007; 9:178-83.

Yancovitz M, Finelt N, Warcha MA, Christos PJ, Mazumdar M, Shapiro RL, Pavlick AC, Osman I, Polsky D, Berman. Role of Radiologic Imaging at Time of Initial Diagnosis of Stage T1b-T3b Melanoma. Cancer. 2007. Sep 1;110(5): 1107-14.

Guth AA, Roses DF, Shanker BA, Axelrod DA, Singh B, Shapiro RL, Hiotis K, Diflo T, Cangiarella JF. A Decade of Change: An Institutional Experience with Breast Surgery in 1995 and 2005. Submitted for publication. 2007.

Shapiro RL, Culliford A IV. Surgical treatment of malignant cutaneous neoplasms. In McCarthy J (ed). Current Therapy in Plastic Surgery: pp. 45-52. Philadelphia, Saunders Elsevier. 2005.

Mikhail M, Velazquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L,
Spira J, Mir, Panageas KS, Polsky D, Osman I. PTEN Expression in melanoma: Relationship with patient survival, Bcl-2 expression and proliferation. Clinical Cancer Research 2005 Jul 15; 11 (14): 5153-7. PMID: 16033830.

Shapiro RL. Malignant melanoma. In Greer, SE (ed). Handbook of Plastic Surgery: pp. 111-116. New York, Marcel Dekker, Inc. 2004.

Formenti SC, Truong MT, Goldberg JD, Mukhi V, Rosenstein B, Roses D, Shapiro R, Guth A, Dewyngaert JK. Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):493-504.

Reynolds SR, Zeleniuch- Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, , Bystryn JC. Vaccine-induced CD8+ T cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clinical Cancer Research. 2003; 9: 657-662.

Naik AM, Joseph KA, Harris M, Davis C, Shapiro R, Hiotis KL. Indigent breast cancer patients among all racial and ethnic groups present with more advanced disease compared with nationally reported data. Am J Surg 2003 Oct; 186(4): 400-403.

Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A, Bystryn JC. Changes in the presence of multiple markers of circulating melanoma cells correlates with clinical outcome in patients with melanoma. Clinical Cancer Research. 2003; 9(4).

Shapiro RL. Surgical approaches to malignant melanoma -Practical guidelines. Dermatol Clin 2002 Oct;20(4):681.

Lasky DS, Shapiro RL, Harris MN, Roses DF, Reynolds SR, Bystryn JC. Long term survival of stage IV melanoma patients treated with a polyvalent shed antigen melanoma vaccine. 2002. Submitted for publication.

Symmans WF, Yee HT, Volm MD, Demaria S, Chirboga L, Shapiro RL, Formenti SC, Muggia F. P-glycoprotein expression in breast cancer is not induced by paclitaxel chemotherapy. 2002. Submitted for publication.

Bystryn JC, Albrecht J, Reynolds SR, Rivas MC, Oratz R, Shapiro RL, Roses DF, Harris MN, Conrad A. Decrease in circulating tumor cells as an early marker of therapy effectiveness. Recent Results in Cancer Research 2001; 158: 204-7.

Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clinical Cancer Research 2001 Jul; 7(7): 1882-7.

Cooper JS, Chang WS, Oratz R, Shapiro RL, Roses DF. Elective radiation for high-risk malignant melanomas. The Cancer Journal. 2001; 7(6): 498-502.

Demaria S, Volm M, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clinical Cancer Research 2001 Oct; 7(10): 3025-30.

Cangiarella J, Waisman J, Shapiro RL, Simsir A. Cytologic features of
tubular adenocarcinoma of the breast by aspiration biopsy.
Diagnostic Cytopathology. 2001; 25(4): 1-8.

Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC. Identification of HLA-A*3, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. J of Immunol Methods. 2000; (244): 59-67.

Cangiarella J, Symmans WF, Shapiro RL, Roses DF, Cohen JM, Chhieng D, Harris MN, Waisman J. Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. Cancer 2000 Jun 25; 90(3): 162-6.

Chhieng C, Fernandez G, Cangiarella J, Cohen JM, Waisman J, Harris MN, Roses DF, Shapiro RL, Symmans WF. The probability of invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine needle aspiration. Cancer Cyotpathol. 2000; 90 (2): 96-101.

Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine needle aspiration: Implications for early prediction of breast cancer response to neoadjuvant treatment. Clinical Cancer Research. 2000; 6: 4610-4617.

Roses DF, Brooks AD, Harris MN, Shapiro RL, Mitnick J.
Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg. 1999; 230(2): 194-201.

O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Anti-angiogenic effects of 9-Amino-20(s)-Camptothecin (9-AC), Topotecan (TTN), and CPT-11 studied in the mouse cornea model. J. of Clinical Cancer Res.1999; 5: 181-187.

Bystryn JC, Albrecht J, Oratz R, Shapiro RL, Chen DL, Rivas Mc, Conrad A. Effect of vaccine therapy on the presence of melanoma cells in the circulation. Journal of Investigative Dermatology 1999; 112(4): 643.

Zeng Z, Melamed J, Symmans PJ, Cangiarella JF, Shapiro RL, Peralta H, Symmans WF. The epidermis overlying benign proliferative nipple duct lesions may exhibit CAM 5.2 and CK7 immunoreactive cells which mimic Paget's disease. Amer J Surgical Pathol. 1999; 23: 1349-1355.

Seghezzi G, Patel S, Ren CJ, Pintucci G, Gualandris A, Robbins E, Shapiro R, Galloway AC, Rifkin DB, Mignatti P. Fibroblast Growth Factor-2 (FGF-2) induces Vascular Endothelial Growth Factor (VEGF) expression in the endothelial cells forming capillaries: An autocrine mechanism of angiogenesis. J. of Cell Biology. 1998; 141(7): 1659-1673.

Montesinos MC, Shapiro R, Desai A, Cronstein BN. An adenosine A2a receptor agonist (CGS-21680) promotes wound closure in normal and urokinase plasminogen knockout (uPA-KO) but not tissue plasminogen activator knockout (tPA-KO) mice. Arthritis and rheumatism 1998; 41(9): S191-S191.

Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn J-C. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp 100, Tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J of Immunology. 1998; 161: 6970-6976.

Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB. Repression of Interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cellular Immunology. 1998;190: 141-155.

Ren CJ, Ueda F, Roses DF, Harris MN, Mignatti P, Rifkin DB, Shapiro RL. Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator deficient mice. J of Surgical Research. 1998; 77: 126-131.

Applebaum J, Reynolds S, Knispel J, Oratz R, Shapiro RL, Bystryn J-C. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. J NCI. 1998; 90(2): 146-149.

Glat PM, Longaker MT, Jelks EB, Spector JA, Roses DF, Shapiro RL, Zide BM, Jelks GW. Periorbital melanocytic lesions: Excision and reconstruction in 40 patients. Plast Reconst Surgery. 1998; 102(1); 19-27.

Cangiarella J, Symmans WF, Cohen JC, Goldenberg A, Shapiro RL, Waisman J. Malignant melanoma metastatic to the breast. Cancer Cytopathology. 1998; 84(3): 160-162.

Shapiro RL, Duquette J, Nunes I, Roses DF, Harris MN, Wilson EL, Rifkin DB. Urokinase-type plasminogen activator deficient mice are predisposed to Staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Amer J Pathol. 1997; 150: 359-369.

Reynolds SR, Oratz R, Shapiro RL, Hao P, Yun Z, Fotino M, Vukmanovic S, Bystryn JC. Stimulation of CD8+ T Cell responses to MAGE-3 and MELAN A/ Mart-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer.1997; 72: 972-976.

Krinsky GA, Johnson G, Rofsky N, Shapiro R, Chang B, Weinreb JC. Venous aneurysms: Diagnosis with the layered gadolinium sign. JCAT. 1997; 21(4): 623-627.

Shapiro RL, Duquette J, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL, Rifkin DB. Induction of primary cutaneous melanocytic neoplasms in uPA-deficient and wildtype mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Research.1996; 56, 3597-3604.

Glat PM, Spector JA, Roses DF, Shapiro RL, Harris MN, Beasley RW,
Grossman JAI. The management of pigmented lesions of the nail bed.
Ann Plast Surg. 1996; 37: 125-134.

Bystryn J-C, Shapiro RL, Harris MN, Roses DF, Oratz R. The use of vaccines in the treatment of malignant melanoma. Clinics in Dermatology. 1996; 14: 337-341.

Nunes I, Munger JS, Harpel JG, Nagano Y, Shapiro RL, Gleizes P-E, Rifkin DB. Structure and activation of the large latent transforming growth factor-* complex. Int J Obesity. 1996; 20(3), S4-8.

Bystryn JC, Oratz R, Shapiro RL, Johnston D, Harris MN, Roses DF, Jacquotte AZ, Chen DL, Lax A. Potentiation of melanoma vaccine activity by IL-2 liposomes. J Invest Derm.1996:106(4); 938 (794).

Nunes I, Shapiro RL, Rifkin DB. Characterization of the activation of
latent TGF-* in murine peritoneal macrophages. J Immunology. 1995; 155: 1450-1459.

Bystryn J-C, Shapiro RL, Oratz R. Partially purified tumor antigen vaccines. In: Devita VT Jr., Hellman S, Rosenberg SA (eds): Biological Therapy of Cancer, 2nd edition, pp 668-679. Philadelphia, JB Lippincott, 1995.

Harris MN, Shapiro RL, Roses DF . Malignant melanoma: Primary surgical treatment (Excision and lymph node resection) based on pathology and staging. Cancer.1995; 75: 715-725.

Glat PM, Shapiro RL, Harris MN, Roses DF, Grossman JAI.
Management considerations for melanonychia striata and melanoma of the hand. In: Akelman E (ed.): Tumors of the Hand and Forearm, Hand Clinics 11(2): pp.183-190. Philadelphia, W.B. Saunders, 1995.

Jellinek D, Green LS, Bell C, Lynott CK, Gill N, Vargese C, Kirchenheuter G, McGee DPC, Abesinghe P, Pieken WA, Shapiro R, Rifkin DB, Moscatelli D, Janjic N. Potent 2'-Amino-2'-Deoxypyrimidine RNA inhibitors of Basic Fibroblast Growth Factor. Biochemistry. 1995; 34: 11363-11372.

Bystryn J-C, Shapiro RL, Roses DF, Oratz R. Melanoma vaccines.
Hem/Onc Annals. 1993; 1: 301-307.

Roses DF, Harris MN, Shapiro RL. Surgical management of cutaneous
malignant melanoma. Hem/Onc Annals. 1993; 1: 263-274.

Marti JL, Harris MA, Naik A, Shapiro RL, Guth AA, Hiotis KL. Racial differences in breast cancer presentation. Submitted for publication.

Shapiro RL, Verga T, Cangiarella J, Harris MN, Roses DF. Malignant Melanoma in Teenagers and Young Adults Under 30. Manuscript in preparation

Shapiro RL, Verga T, Cangiarella J, Harris MN, Roses DF. Malignant Melanoma in Russian Immigrants. Manuscript in preparation.


[ Back to Top ]

Detection of BRAF Kinase mutations in melanoma, ovarian, and prostate carcinomas - evidence for tumor heterogeneity in clinical samples. AJ Litterman, M Yancovitz, R Shapiro, R Berman, A Pavlick, F Darvishian F, S Blank, P Lee, I Osman, D Polsky. ASCO 2009 Annual Meeting. Poster.

Mebendazole Inhibits Melanoma Xenograft Growth by Targeting Bcl-2. N Doudican, R Pennell, T Tu, L Liebes, AC Pavlick, RL Shapiro, RS Berman, JD Goldberg, I Osman, SJ Orlow. ASCO 2009 Annual Meeting. Poster.

The clinical relevance of microRNA in metastatic melanoma. MF Segura, J Zakrzewski, A Gaziel, D Hanniford, M Kushnir, M Hoshen, AC Pavlick, RS Berman, RL Shapiro, I Belitskaya-Levy, A Chajut, D Cohen, I Osman, E Hernando. ASCO 2009 Annual Meeting. Oral presentation.
Prognostic factors of survival in melanoma patients with brain metastases: a prospective analysis 2002 - 2008. J Zakrzewski, L Geraghty, D Krich, PJ Christos, M Mazumdar, F Darvishian, AC Pavlick, RL Shapiro, RS Berman, I Osman. ASCO 2009 Annual Meeting. Poster.
Evaluation of a role for pigmentation and DNA repair genes in melanoma predisposition. P Manga, JD Goldberg, I Belitskaya-Levy, I Lobach, D Polsky, AC Pavlick, RL Shapiro, RS Berman, I Osman, H Ostrer. ASCO 2009 Annual Meeting. Oral presentation.
Evaluation of the melanocortin-1-receptor gene in melanoma predisposition and progression. S Sidash, H Ostrer, JD Goldberg, I Belitskaya-Levy, I Lobach, D Polsky, RL Shapiro, RS Berman, I Osman, P Manga. Submitted to the ASCO 2009 Annual Meeting.
Wen, DF Roses, DM, Axelrod, AA Guth, RL Shapiro, B Singh Impact of micropapillary type of Ductal Carcinoma in Situ on rate of re-excision after breast conserving therapy. XXVII International Congress of the International Academy of Pathology,
12-17 Oct, 2008, Athens, Greece.

Lee A, Guth A, Singh B, Roses D, Axelrod D, Hiotis K, Shapiro RL, Schnabel F, Mercado C, Cangiarella J. Phylloides Tumors of the Breast: Preoperative Needle Biopsy Reduces Rate of Reexcision. American Society of Breast Diseases Annual Meeting, April 2008, San Diego, California.

Warycha MA, Yu JZ, Christos P, Darvishian F, Kamino H, Shapiro R, Berman R, Kopf AW, Polsky D, Osman I. Different Clinical Behavior of Nodular Melanoma (NM) Compared to Superficial Spreading Melanoma (SSM) at New York University from 1972 to present. Proceedings of ASCO 2008 Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstract 20001).

Zakrzewski J, Warycha M, Quanhong Ni, Shapiro R, Berman R, A. Pavlick A, Polsky D, Mazumda M, Osman I. Meta-Analysis of Sentinel Lymph Node Positivity in Thin Melanoma (? 1mm). Proceedings of ASCO 2008 Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstract 20032).

Firoz EF, Warycha M, Shapiro R, Berman R, Kamino H, F. Darvishian F, Rolnitzky L, Goldberg J, Osman I, Polsky D. MDM2 SNP309 and Melanoma Risk among Women. ASCO Annual Meeting in Chicago , IL May 30 - June 3, 2008: General Poster Session.

Litterman A, Pollens D, Warycha M, Shapiro R, Berman R, Pavlick A, Blank S, Lee P, Osman I, Polsky D. Tumor Heterogeneity: Evidence from BRAF V600E mutation detection. Proceedings of ASCO 2008 Annual Meeting. J Clin Oncol 26:2008 (May 20 suppl; abstract 20022).

Doudican N, Rodriguez A, Pavlick AC, Shapiro R, Osman I, Orlow SJ. Mebendazole Induces Apoptosis in Distinct Melanoma Subtypes via Bcl-2 Dependent Mechanism. Proceedings of ASCO 2008 Annual Meeting. J Clin Oncol 26:2008 (May 20 suppl; abstract 20008).

Segura MF, Hanniford D, Guijarro MV, Menendez S, Pavlick A, Berman R, Shapiro R, Polsky D, Osman I, Hernando E. Role of microRNA in melanoma genesis and progression.. ASCO 2008.

Bogunovic* D, O'Neill D*, Adams S, Wang J, Darvishian F, Pavlick A, Shapiro R, Zavadil J, Osman I, Bhardwaj N. Gene expression profile for metastatic melanoma associated with prolonged patient survival. ASCO 2008.

Berman R, Glick J, Warycha M, de los Santos P, Pavlick A, Shapiro R, Polsky D, Osman I, Friedman K. Prognostic significance of multiple lymphatic channels within a single mapped basin in melanoma patients. ASCO 2008.

Friedman K, Spira J, Pavlick A, Shapiro R, Berman R, Osman I. 3D rendered PET/CT for preoperative assessment of locally recurrent melanoma.. ASCO 2008.

Wen, Y. H, Roses, D. F, Axelrod, D. M, Guth, A. A, Shapiro, R. L,
Berman, R, Singh, B. Rate of Re-excision with Breast Conserving
Therapy With and Without Additional Margins in patients with Ductal Carcinoma in Situ Society of Surgical Oncology 61st Annual
Cancer Symposium, March 13-16, 2008, Chicago, IL.

Yu Z, Warycha M, Zakrzewski J, Yee H, Christos P, Berman R, Pavlick A, Shapiro R, Kamino H, Liebes L. Brooks P, Osman I.
Differential expression of Insulin-like growth factor binding protein-4 (IGFBP-4) and Integrin v 3 in melanoma. International Melanoma Congress, New York, NY Nov 30 - June 3, 2007.

Yancovitz M, Yoon J, Warycha M, Zakrzewski JA, Spiro J, Yu JZ,. Gai W, Shapiro RL , Berman RS, Pavlick AC, Meehan S, Kamino H, F. Darvishian F, Osman I, Polsky D. Detection of BRAF mutations in plasma and tissues of patients with metastatic melanoma. International Melanoma Congress, New York NY Nov 30 - June 3, 2007.

Friedman K, Spira J, Pavlick A, Shapiro R, Berman R, Osman I. 30 3-D Rendered PET/CT for preoperative assessment of locally recurrent melanoma. International Melanoma Congress, New York NY Nov 30 - June 3, 2007.

Yancovitz M, Yoon J, Warycha M, Zakrewski JA, Spira J, Wu JZ, Gai W, Shapiro RL, Berman RS, Pavlick AC, Meehan S, Kamino H, Darvashian F, Osman I, Polsky D. Detection of BRAF Mutations in Plasma and Tissues of Patients with Metastatic Melanoma (M-25). Pigment Cell Research. 2007 Dec; 20 (6).

Yu JZ, Warchya M, Zakrewski JA, Yee H, Christos P, Beramn RS, Pavlick AC, Shapiro RL, Kamino H. Liebes L, Brooks P, Osman I. Differential Expression of Insulin-like Growth factor Binding Protein-4 (IGFBP-4) and Integrin avb in Melanoma Progression (M-23). Pigment Cell Research 2007 Dec; 20 (6).

Yu JZ, Yee H , Warycha M, Christos P, Berman R, Pavlick A, Shapiro R, Liebes L, Brooks p, Osman I. Differential Expression of the Insulin like Growth Factor Binding Protein-4 (IGFBP4) in Melanoma Progression (8550) Supplement to Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings. 25(18S) Part I of II:484s.

Zakreewski J, Ng B, Warycha M, Christos P, Shapiro R, Berman R, Pavlick A, Liebes L, Brooks P, Osman I.. Shedding of the Distinct Epitope (HU177) in Sera of Melanoma Patients (8557) Supplement to Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings. 25(18S) Part I of II:487s.

Wen YH, Roses DF, Axelrod DA, Guth AA, Shapiro RL, Cangiarella JF, Zigurdis N, Darvashian F, Singh B. Prophylactic Mastectomy - Trends in Pathologic Findings; Abstract #. 30th Annual San Antonio Breast Cancer Symposium; San Antonio, Texas; December 2007.

Wen YH, Roses DF, Axelrod DA, Guth AA, Shapiro RL, Cangiarella JF, Zigurdis N, Darvashian F, Singh B. Breast Carcinoma in Women 30 Years and Younger. Abstract P61; SSO 60th Annual Cancer Symposium; Washington DC; March 2007.

Yancovitz M, Finelt N, Warycha M, Christos M, Mazumdar M, Shapiro R, Pavilick A, Osman I, Polsky D, Berman RS. Role of Radiologic Imaging at Time of Initial Diagnosis of stage T1b-T3b Melanoma. Abstract P118; SSO 60th Annual Cancer Symposium; Washington DC; March 2007.

Shanker BA, Guth AA, Roses DF, Axelrod DA, Singh B, Shapiro RL, Diflo T, Cangiarella JA. Trends in Breast Cancer Surgery: Comparison of an Institutional Experience Between 1995 and 2005. Abstract P186; SSO 60th Annual Cancer Symposium; Washington DC; March 2007.

Y H Wen, D F Roses, D M Axelrod, A A Guth, R L Shapiro, J Cangiarella, N Ziguridis, F Darvishian, C Mercado, B Singh. Prophylactic mastectomy trends in pathology
Findings. San Antonio Breast Cancer Symposium, Dec 13-17, 2007.

Y H Wen, D F Roses, D M Axelrod, A A Guth, R L Shapiro, J Cangiarella, N Ziguridis, F Darvishian, C Mercado, B Singh. Impact of Complete Removal of Breast Carcinoma by Aggressive Biopsy Techniques. United States and Canadian Academy of Pathology's 96th Annual Meeting, March 24-30, 2007 in San Diego, CA.

V Richards, D F Roses, D M Axelrod, A A Guth, R L Shapiro, J Cangiarella, N Ziguridis, F Darvishian and B Singh. Accuracy of Intraoperative Sentinel Lymph Node Evaluation for Breast Cancer. United States and Canadian Academy of Pathology's 96th Annual Meeting, March 24-30, 2007 in San Diego, CA.

Tepper O, Karp N, Small K, Rudolph L, Roses D, Shapiro RL, Guth A,
Axelrod D, Choi M. Three-Dimensional Imaging in Breast Reconstruction: A
Useful Adjunct to Surgical Planning and Assessment . Abstract # 550567. 29th
Annual San Antonio Breast Cancer Symposium; San Antonio, Texas;
December 2006.

Singh B, Ziguridis N, Guzman SA, Axelrod DA. Shapiro RL, Guth AA,
Skinner KA, Cangiarella J, Roses DF. Qualitative criteria to evaluate sentinel
lymph node frozen sections for breast cancer. Abstract. 29th Annual San
Antonio Breast Cancer Symposium; San Antonio, Texas; December 2006.

Hiotis KL, Marti JL, Harris MA, Naik A, Shapiro RL, Guth AA. Breast
Cancer Detection in a Minority Population: Can We Succeed in Early
Diagnosis?. 14th Annual Congress on Women's Health; Hilton Head, North
Carolina. June 2006.

Hiotis KL, Marti JL, Harris MA, Naik A, Shapiro RL, Guth AA. Breast
Cancer Screening in a Minority Underserved Population. 14th Annual Retreat
NYU Cancer Institute; New York, NY. June 2006.

Shapiro RL. Sentinel Lymph Node Biopsy Update 2006. Advances in Dermatology 2006, NYU Medical Center, June 16, 2006.

Tepper O, Karp N, Small K, Shapiro R, Guth A, Axelrod D, Choi M. Optimizing Symmetry in Implant-Breast Reconstruction with the Use of Three-Dimensional Imaging. American Society of Breast Surgeons, 7th Annual Meeting; Baltimore, Maryland; April 2006.

Velazquez EF, Yancovitz M, Sorhaindo L, Bogunovic D, O'Neil D,
Shapiro R, Pavlick A, Berman R, Bhardwaj N, Spira J, Christos DP, Nanus D, Polsky D, Osman I. Neutral Endopeptidase (NED) Overexpression is Associated with Progression in Malignant Melanoma and is a Potential Target of Treatment. United States and Canadian Academy of Pathology Academy of Pathology, 2006 Annual Meeting (Abstract Submitted).

Velazquez EF, Jungbluth AA, Osman I, Yancovitz M, Adams S, O'Neil D,
Albukh T, Pavlick A, Polsky D, Shapiro R, Berman R, Spira J, Busam K, Bhardwaj N. Expression of Cancer Testis (CT) Antigen NY-ESO-1 in Primary and Metastatic Malignant Melanoma: Correlation with Prognostic Factors and Potential Role in Melanoma Vaccine. United States and Canadian Academy of Pathology Academy of Pathology, 2006 Annual Meeting (Abstract Submitted).

Wen Yh, Roses DF, Axelrod DM, Guth AA, Shapiro RL, Cangiarella J, Zigurdis N, Darvishian F, Singh B. Breast Carcinoma in Women 30 Years and Younger. 2006. (Abstract Submitted).

Wen Yh, Roses DF, Axelrod DM, Guth AA, Shapiro RL, Cangiarella J, Zigurdis N, Darvishian F, Singh B. Impact of Removal of Breast Carcinoma by Aggressive Biopsy Techniques. 2006. (Abstract Submitted).

V Richards, Sun W, Axelrod DM, Shapiro RL, Guth AA, Roses DF, Zigurdis N, Cangiarella J, Darvishian F, Singh. Accuracy of Intraoperative Sentinel Lymph Node Evaluation for Breast Cancer. 2006. (Abstract Submitted).

Marti J, Naik A, Joseph K, Harris M, Davis C, Shapiro RL, Hiotis K. Racial Differences in Breast Cancer Presentation. Abstract and Poster Presentation. Sixth Milan Breast Cancer Conference; Milan, Italy, June 2004.

Naik A, Joseph KA, Harris M, Davis C, Shapiro RL, Hiotis K. Epidemiologic and Pathologic Characteristics of Chinese Breast Cancer Patients. Fifth Milan Breast Cancer Conference; Milan, Italy June 2003.

Naik A, Joseph KA, Harris M, Davis C, Shapiro RL, Hiotis K. Indigent Breast Cancer Patients Among All Racial and Ethnic Groups Present with More Advanced Disease Compared to Nationally Reported Data. Abstract and Poster Presentation. Association of Breast Surgeons; Atlanta, Florida; May 2003.

Chuang N, Shapiro RL, Mignatti P, Roses DF, Shammamian P.
depletion of polymorphomononuclear neutrophils (PMNs)
inhibits angiogenesis in vivo. Surgical Form, Surgical Oncology Section I, American College of Surgeons. 2000.

Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti S,
Muggia F, Symmans WF. Increase in the lymphocytic infiltrate in breast cancer after neoadjuvant paclitaxel chemotherapy. (#2120). Proc AACR. 2000.

Symmans WF, Yee HT, Volm MD, Demaria S, Chiriboga L, Shapiro RL, Kim AY, Muggia F. P-glycoprotein expression expression is not induced by the first dose of neoadjuvant paclitaxel treatment. San Antonio Breast cancer symposium, December 2000, Breast Cancer Res Treat 2000; 64(1): 71A.

Bystryn JC, Oratz R, Shapiro RL, Harris MN, Roses DF, Zeleniuch-Jacquotte, Chen DL, Rivas MC, Hankinson T. Double-blind, placebo-controlled, trial of a shed, polyvent, melanoma vaccine in stage III melanoma. Proc of the American Society of Clinical Oncology.1999; 18:
434a.

Oratz R, Albrecht J, Shapiro RL, Harris MN, Roses DF, Chen DL, Rivas MC, Conrad A, Bystryn JC. Assay of circulating melanoma cells as an indicator of the efficacy of melanoma vaccine therapy. Proc of the American Society of Clinical Oncology.1999; 18: 553a.
Chuang N, Shamamian P, Yee HT, Mignatti P, Roses DF, Shapiro RL. Polymorphonuclear neutrophils (PMNs) modulate angiogenesis in vivo (#3682). Proc AACR. 1999; 40: 558.

Symmans WF, Volm MD, Shapiro RL, Perkins AB, Chhieng DC, Pagano M, Yee HT, Cangiarella JF, Demaria S, Formenti S, Muggia F. Use of fine needle aspiration to measure cancer cell apoptotic and mitotic responses during neoadjuvant paclitaxel chemotherapy in women with locally advanced breast cancer. 1999. Proc AACR.

Volm MD, Yee H, Symmans WF, Formenti S, Oratz R, Shapiro R, McMullen H, Shore R, Muggia F. Her2 status predicts response to
preoperative paclitaxel in patients with breast cancer. Proc of the American Society of Clinical Oncology.1999; 18: 104a.

Chuang N, Shetty R, Cooper JS, Shapiro RL, Mignatti P, Shamamian P.
Radiation inhibits basic Fibroblast Growth Factor (bFGF) induced angiogenesis. Proc of the Association for Academic Surgery, Thirty-Third Annual Meeting. 1999.

Chuang N, Shamamian P, Roses DF, Rifkin DB, Shapiro RL. Melanoma growth in wild-type, urokinase-type plasminogen activator, and tissue-type plasminogen activator mice. Surgical Form, Surgical Oncology Section IV, American College of Surgeons. October 1999.

Shapiro RL, Johnston D, Oratz R, Harris MN, Roses DF, Zeleniuch-Jacquotte, Beck A, Bystryn JC. Effect of GM- CSF Liposomes on the immunogenicity of a polyvalent melanoma vaccine. Submitted to Proc of the American Society of Clinical Oncology.1999; 18: 440a

Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti S, Muggia F, Symmans WF. Increase in the lymphocytic infiltrate in breast cancer after neoadjuvant paclitaxel chemotherapy. 1999. AACR.

Chuang N, Ren CJ, Mendoza S, Shamamian P, Roses DF, Rifkin DB, Chachoua A, Shapiro RL. Inhibition of angiogenesis and matrix metalloproteinase-2 activity by Dexrazoxane (Zinecard) may mediate its antitumor effects. 1998. Surgical Forum, ACS; XLIX: 424-425.

Bystryn JC, Oratz R, Shapiro RL, Harris MN, Roses DF, Jacquotte A, Chen DL, Rivas M. Phase 3, Double blind trial of a shed, polyvalent, melanoma vaccine in stage III melanoma. Proc of the American Society of Clinical Oncology.1998; 17: 434a.

Fernandez G, Chhieng DC, Waisman J, Cangiarella J, Cohen J-M, Harris MN, Roses DF, Shapiro RL, Symmans WF. The probability of invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma (ACA) by fine needle aspiration (FNA). International Academy of Pathology, October 1998.

Oratz R, Reynolds S, Shapiro RL, Harris MN, Roses DF, Johnston D, Jacquotte A, Hankinson T, Bystryn JC .Phase I/II trial of a shed, polyvalent, melanoma vaccine combined with Interferon alpha-2b in stage IV melanoma. Proc of the American Society of Clinical Oncology.1998; 17: 523a.

O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Anti-Angiogenic Effects of 9-Amino-20(s)-Camptothecin (9-AC), Topotecan (TTN), and CPT-11 studied in the mouse cornea model. Proc of the American Society of Clinical Oncology.1998; 17: 248a.

Chuang N, Shapiro RL, Ren CJ, Roses DF, Rifkin DB. Melanoma lung metastases in wild-type urokinase- and tissue- type plasminogen activator knockout mice. Proc of the Society of University Surgeons.1998.
Bystryn JC, Reynolds SR, Shapiro RL, Oratz R, Harris M, Roses D. Upregualtion of HLA expression by Interferon-alpha 2B in vaccine treated melanoma patients. Proc of the American Association of Cancer Research. 1998: 39; 357.

Reynolds SR, Celis E, Sette A, Shapiro RL, Oratz RO, Bystryn JC. CD8+ T Cell epitopes on MAGE-3, Melan A/MART-1, gp 100, tyrosinase, MSH, and TRP-2 that are immunogenic in vivo in melanoma patients. Proc of the American Association of Cancer Research. 1998: 39; 369.

Chuang N, Ren CJ, Roses DF, Rifkin DB, Shapiro RL. Melanoma lung metastases in wild-type urokinase- and tissue- type plasminogen activator knockout mice. Proc of the American Association of Cancer Research. 1998: 39; 297.

Zeng Z, Melamed J, Symmans PJ, Cangiarella J, Shapiro RL, Prealta HR, Symmans WF. Pagetoid spread of CAM5.2 and CK7 immunoreactive cells into nipple epidermis overlying benign proliferative nipple duct lesions. Modern Pathol. 1998: 11(1); 31A.

O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Muggia F, Potmesil M. Anti-angiogenic effects of 9-Amino-20(s)-Camptothecin (9-AC), Topotecan (TTN), and Camptosar (CPT-11). Poster presentation at 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, June 16-19, 1998.

O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Anti-angiogenic effects of Camptothecins. Podium presentation National Medical Oncology Fellows Forum, Tuscon, Arizona, March 1998.

Montesinos MC, Shapiro RL, Desai A, Cronstein BN. An adenosine A2a receptor agonist (CGS-21680) promotes wound closure in normal and urokinase plasminogen activator knockout (uPA-KO) but not tissue plasminogen activator knockout (tPA-KO) mice. Proc of ACR, November 1998.

Chhieng DC, Fernandez G, Cangiarella JF, Cohen JM, Waisman J, Harris MN, Roses DF, Shapiro RL, Symmans WF. Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine needle aspiration. Proc of 22nd International Congress of the International Academy of Pathology. October 1998.

Oratz R, Reynolds SR, Shapiro RL, Harris MN, Roses DF, Vukmanovic S, Bystryn J-C. A Polyvalent melanoma vaccine induces MAGE-3 and MART-1/Melan-A Specific CD8+ T cell responses that correlate with clinical outcome. Proc of the American Society of Clinical Oncology. 1997; 16: 432a.

Seghezzi G, Patel S, Ren CJ, Pintucci G, Gualandris A, Robbins E, Shapiro R, Galloway AC, Rifkin DB, Mignatti P. Fibroblast Growth Factor-2 (FGF-2) induces Vascular Endothelial Growth Factor (VEGF) expression in the endothelial cells forming capillaries: An autocrine mechanism of angiogenesis. Surgical Form, Oncology Section, American College of Surgeons. October 1997.

Ren CJ, Shapiro RL, Roses DF, Harris MN, Eng K, Mignatti P, Rifkin DB. Irsogladine maleate inhibits angiogenesis in vivo. Proc of the Association for Academic Surgery, Thirty-First Annual Meeting. 1997; 157.

Ren CJ, Schwartz JD, Shamamian P, Eng K, Roses DF, Harris MN,
Shapiro RL. Platelet-activating factor receptor antagonist inhibits basic FGF-induced angiogenesis. Proc of the Association for Academic Surgery, Thirty-First Annual Meeting. 1997; 118.

Seghezzi G, Patel S, Ren CJ, Pintucci G, Hernandez H, Kallenbach K, Shapiro RL, Colvin SB, Rifkin DB, Mignatti P, Galloway AC. Autocrine regulation of blood vessel formation by Fibroblast Growth Factor-2 (FGF-2) and Vascular Endothelial Growth Factor (VEGF): A mechanism for tumor angiogenesis. Proc of the Association for Academic Surgery, Thirty-First Annual Meeting. 1997; 241.

Rifkin DB, Shapiro R, Munger J, Duquette J. Proteases, growth factors, and wound healing. Keystone Symposia on Molecular and Cellular Biology, Tissue Engineering: Wound Repair in Context. 1996: J4; 40.

Oratz R, Shapiro RL, Johnston D, Harris MN, Roses DF, Zeleniuch-Jacquotte, Chen D, Lax A, Bystryn JC. IL-2 liposomes markedly enhance the activity of a polyvalent melanoma vaccine. Proc of the American Society of Clinical Oncology.1996; 15, 436.

Reynolds SR, Vukmanovic S, Oratz R, Shapiro RL, Bystryn JC. A polyvalent melanoma vaccine induces a CD8+ T cell response to MART-1 and MAGE-3 peptides. Proc of the American Association of Cancer Research. 1996: 37; 491.

Bystryn JC, Oratz R, Shapiro RL, Johnston D, Reynolds S, Harris MN, Roses DF, Zeleniuch-Jacquotte A. Potentiation of melanoma vaccine immunogenicity by IL-2 liposomes. Cambridge Symposia "Immunology and Immunotherapy of Metastasis". Lake Tahoe, NV.1996.

Bystryn JC, Oratz R, Shapiro RL, Reynolds S, Johnston D, Harris MN, Roses DF, Zeleniuch-Jacquotte AZ. Potentiation of melanoma vaccine immunogenicity by IL-2 liposomes. Cambridge Symposia "Discovery and Development of Tumor Vaccines". Taos, NM.1996

Dosik D, Chachoua A, Oratz R, Shapiro R, Speyer J, Wasserheit C, Frazien A, Downey A, Blum R. Phase I study of IL-1* combined with high dose cisplatin(CDDP) in patients with metastatic melanoma. Proc of the American Society of Clinical Oncology.1996; 15, 440.

Shapiro RL, Duquette J, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL, Rifkin DB. Progression of primary cutaneous melanocytic neoplasms in syngeneic uPA-deficient mice. Proc of the International Workshop on Molecular and Cellular Biology of Plasminogen Activation. 1995: 85.

Bystryn J-C, Oratz R, Shapiro R, Roses D, Harris M, Johnston D. Vaccine treatment of melanoma. Advances in the Biol and Clin Management of Melanoma, Proc 38th Annual Clin Conf Univ Texas
MD Anderson Cancer Center. 1995; 53-54.

Roses DF, Harris MN, Golomb FM, Shapiro RL, Melamed J, Kramer E. Intraoperative lymphatic mapping and sentinel lymphadenectomy in the staging of patients with malignant melanoma. Proc of the New York Surgical Society, Scientific Session. November 8, 1995.

Oratz R, Shapiro RL, Chen D, Harris MN, Roses DF, Bystryn J-C.
Effect of IL-2 liposomes on the immunogenicity of a polyvalent
melanoma vaccine. Proc of the American Society of Clinical
Oncology.1994; 13: 1350.


[ Back to Top ]

Advanced Cardiac Life Support 1988


[ Back to Top ]